Cosette Pharmaceuticals Receives U.S. Patent (US 11,291,628) For Welchol® Chewable Bar, A Novel Oral Drug Delivery System to Deliver Colesevelam Hcl
Innovating Every Day.TM
BRIDGEWATER, N.J.--(BUSINESS WIRE)--#chewable--Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,291,628 for Welchol® Chewable Bar, the Company’s novel drug delivery system of Colesevelam that is easy to handle and ingest, which provides patent protection until 2037.
“Cosette has now obtained valuable patent protection for a novel drug delivery system that can deliver high load therapeutics, increasing patient convenience and compliance. The patent is an important aspect of Cosette’s mission of 'Innovating Every Day' and supports the continued development of our Welchol® franchise,” said President and CEO of Cosette, Apurva Saraf.
Learn more about Welchol® at welchol.com.
About Cosette Pharmaceuticals, Inc.:
Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (in New Jersey and North Carolina) supported by 300+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm.